Morgan Stanley cut its target price for DAMAI ENT due to a significant decline in its share price, which has fallen about 40% since February. This decline reflects concerns over the valuation of its IP business, issues in its film segment, slower revenue from Sanrio-related IP, and profit pressures from overseas expansion investments. The firm also lowered its revenue and profit forecasts for the company for the years 2026 to 2028.
